Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 5NIH 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 7Breast 6Plasma cell 3Tumor-Agnostic 2Gynecologic 2CNS 2Thoracic 1Other solid neoplasm 1Other hematologic neoplasm 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Neoplasm Metastasis 2

Interventions

Specimen Handling 19Biopsy 18Magnetic Resonance Spectroscopy 12Paclitaxel 9trastuzumab deruxtecan 4olaparib 4X-Rays 4Taxes 4nilotinib 3Radiotherapy 3Gemcitabine 3Cisplatin 3Carboplatin 3Bevacizumab 3trametinib 2talazoparib 2pembrolizumab 2omipalisib 2durvalumab 2copanlisib 2aldesleukin 2Vincristine 2Topotecan 2Phantoms, Imaging 2Leucovorin 2Immunoglobulin G 2Fluorouracil 2Doxorubicin 2Disulfides 2Cyclophosphamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × copanlisib × Tumor-Agnostic × Clear all
NCT03842228 2026-05-29

COD

National Cancer Institute (NCI)

Phase 1 Active not recruiting
39 enrolled 15 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT04317105 2026-05-13

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
54 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡